Jan Lötvall (also spelled Lotvall) is a Swedish clinical allergist and scientist working on translational research primarily in the field of asthma. He is the former director of the Krefting Research Centre at the University of Gothenburg[1] and is the Chief Scientific Officer of ExoCoBio.[2][3]
Lötvall's laboratory proposed extracellular vesicles such as exosomes and microvesicles as shuttles of RNA molecules between cells[4] along with several other groups in 2006,[5] 2007,[6] and 2008.[7]
Lötvall was a member of the Executive Committee of the European Academy of Allergy and Clinical Immunology, its secretary general from 2005 to 2009, and its president from June 2009 to June 2011.[8] Lötvall was also co-editor-in-chief of Respiratory Research from 2003 to 2018.[9] He was the first president of the International Society for Extracellular Vesicles (2012–2016) and chaired the first society meeting in Gothenburg, in April 2012.[10] Lötvall became Editor-in-Chief of Journal of Extracellular Vesicles in 2019.
Lötvall studied medicine at the Karolinska Institutet in Stockholm (1981–1985) and graduated from the Medical School of the University of Gothenburg in 1987. He became interested in asthma research in the mid-1980s. After studying as a visiting fellow at the National Heart and Lung Institute, London from 1988 to 1990), Lötvall defended his thesis in February, 1991. He trained in both pharmacology and allergology, and became a specialist in these areas in 1997 and 1999, respectively. He became associate professor (docent) at the University of Gothenburg in 1993 and full professor of clinical allergology in 2002. He is currently Chief Scientific Officer of ExoCoBio.[11][12]
References edit
- ^ "Krefting Steering Committee - Krefting Research Centre, University of Gothenburg, Sweden". Retrieved 2011-01-03.
- ^ "ExoCoBio website".
- ^ "ExoCoBio's First Global Regenerative Aesthetic Exosome Summit". Retrieved 2024-01-15.
- ^ Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (June 2007). "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells". Nature Cell Biology. 9 (6): 654–9. doi:10.1038/ncb1596. PMID 17486113. S2CID 8599814.
- ^ Baj-Krzyworzeka, M.; Szatanek, R.; Weglarczyk, K.; Baran, J.; Urbanowicz, B.; Brański, P.; Ratajczak, M. Z.; Zembala, M. (2006). "Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes". Cancer Immunology, Immunotherapy. 55 (7): 808–818. doi:10.1007/s00262-005-0075-9. PMC 11030663. PMID 16283305. S2CID 25723677.
- ^ Aliotta, J. M.; Sanchez-Guijo, F. M.; Dooner, G. J.; Johnson, K. W.; Dooner, M. S.; Greer, K. A.; Greer, D.; Pimentel, J.; Kolankiewicz, L. M.; Puente, N.; Faradyan, S.; Ferland, P.; Bearer, E. L.; Passero, M. A.; Adedi, M.; Colvin, G. A.; Quesenberry, P. J. (2007). "Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: A novel mechanism for phenotype modulation". Stem Cells. 25 (9): 2245–2256. doi:10.1634/stemcells.2007-0128. PMC 3376082. PMID 17556595.
- ^ Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO (Dec 2008). "Glioblastoma microvesicles". Nature Cell Biology. 10 (12): 1470–6. doi:10.1038/ncb1800. PMC 3423894. PMID 19011622.
- ^ "Executive Committee". European Academy of Allergy and Clinical Immunology. Retrieved 2011-01-03.
- ^ Lotvall J, Panettieri Jr RA (2018). "Thank you and farewell after 15 years editing Respiratory Research". Respiratory Research. 19 (232): 232. doi:10.1186/s12931-018-0929-2. PMC 6258390. PMID 30477500.
- ^ "Executive Board (2012-2014) | ISEV - International Society for Extracellular Vesicles". ISEV. Archived from the original on 2013-08-05. Retrieved 2012-10-08.
- ^ "ExoCoBio website".
- ^ "ExoCoBio's First Global Regenerative Aesthetic Exosome Summit". Retrieved 2024-01-15.